68
688177.SHG Bio-Thera Solutions Ltd
- Market cap
- CNY 7.35B
- P/E
- -
- P/B
- 159.80x
- ROE
- -1,033.9%
- Dividend yield
- 0.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688177.SHG undervalued?
Graham numberThe Graham number of Bio-Thera Solutions Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bio-Thera Solutions Ltd fundamental analysis
No fundamental analysis for Bio-Thera Solutions Ltd yet.
Bio-Thera Solutions Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent gliob…
Full company profileBio-Thera Solutions Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bio-Thera Solutions Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.76M | 2.01M | 0.00 | 700K | 185M | 837M | 455M | 705M | 743M | 935M | 1.06B |
| Gross Profit | 842K | 1.29M | 0.00 | 572K | 165M | 801M | 265M | 511M | 514M | 738M | 864M |
| Operating Income | -144M | -239M | -554M | -1.02B | -547M | 84.3M | -495M | -393M | -496M | -346M | -414M |
| EBITDA | - | -212M | -504M | -966M | -451M | 165M | -396M | -299M | -400M | -207M | -422M |
| Net Income | -137M | -236M | -553M | -1.02B | -513M | 81.9M | -480M | -395M | -510M | -332M | -444M |
| EPS | - | -0.67 | -1.56 | -2.89 | -1.24 | 0.20 | -1.16 | -0.95 | -1.23 | -0.80 | -1.07 |
| Balance Sheet | |||||||||||
| Total Assets | 708M | 619M | 1.02B | 1.01B | 2.39B | 2.62B | 2.18B | 2.29B | 2.21B | 2.29B | 2.54B |
| Total Liabilities | 174M | 271M | 219M | 384M | 388M | 530M | 572M | 1.07B | 1.50B | 1.91B | 2.50B |
| Shareholders' Equity | 534M | 348M | 801M | 631M | 2.01B | 2.09B | 1.61B | 1.21B | 708M | 376M | 42.9M |
| Cash & Short-term Investments | 8.42M | 33.4M | 112M | 39.1M | 284M | 847M | 166M | 164M | 290M | 219M | 308M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -116M | -237M | -528M | -598M | -358M | 236M | -413M | -461M | -55.7M | -82.1M | - |
| Capital Expenditure | 119M | 161M | 318M | 74.8M | 253M | 77.9M | 259M | 276M | 127M | 122M | 325M |
| Free Cash Flow | - | -398M | -846M | -673M | -611M | 158M | -672M | -780M | -183M | -204M | -235M |
| Ratios | |||||||||||
| ROE | -25.6% | -67.8% | -69.0% | -162.1% | -25.6% | 3.9% | -29.9% | -32.5% | -72.1% | -88.3% | -1,033.9% |
| ROA | -19.3% | -38.1% | -54.2% | -100.8% | -21.4% | 3.1% | -22.0% | -17.3% | -23.1% | -14.5% | -17.5% |
| Net Profit Margin | -4,942.1% | -11,723.3% | - | -146,088.8% | -277.4% | 9.8% | -105.6% | -56.0% | -68.7% | -35.5% | -41.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bio-Thera Solutions Ltd dividends
- Dividend yield
- 0.28%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 20.4M | 0.05 | - |
| 2024 | CNY 20.6M | 0.05 | - |
| 2023 | CNY 5.67M | 0.01 | - |
| 2022 | CNY 165K | 0.00 | - |
| 2021 | CNY 553K | 0.00 | 0.7% |
| 2020 | CNY 3.85M | 0.01 | - |
| 2019 | CNY 621K | 0.00 | - |
| 2018 | CNY 621K | 0.00 | - |
| 2017 | CNY 621K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Bio-Thera Solutions Ltd
- Insiders 70.19%
- Institutions 6.18%
- Public & others 23.64%
- Shares outstanding 414M
- Free float 116M
Bio-Thera Solutions Ltd company profile
- Company name
- Bio-Thera Solutions Ltd
- Ticker
- 688177.SHG
- ISIN
- CNE100003R98
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,426
- Fiscal year end
- December
- Address
- No. 18, Spiral 2nd Road, Guangzhou, China, 510005
- Phone
- 86 20 3220 3220
- Website
- bio-thera.com
About Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer; TOFIDENCE for the treatment of rheumatoid arthritis, polyarticular and systemic juvenile idiopathic arthritis, and cytokine release syndrome; and BETAGRIN for the treatment of acute coronary syndromes. The company also develops BAT2206, a biosimilar drug candidate used to treat psoriasis, Crohn's disease, and ulcerative colitis; BAT2306 to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis; and BAT4406F, BAT6026, BAT2606, and BAT2506 for treatment of various autoimmune diseases. In addition, it develops BAT4306F, BAT1308, BAT1006, BAT4706, BAT6026, BAT7104, BAT7104, BAT8006, BAT8010, BAT8008, and BAT8007 for treatment of oncology; BAT2094 and BAT6024 to treat cardiovascular diseases; and BAT5906 that is in Phase III clinical trial for the treatment for wet age-related macular degeneration and diabetic macular edema (DME). The company has a bios imilars alliance with STADA Arzneimittel AG to cover tocilizumab, an immunosuppressant monoclonal antibody indicated for certain inflammatory conditions. The company collaborates with Avalon Pharmaceuticals on BAT2406, a biosimilar of dupixent (dupilumab) across Saudi Arabia and other Middle Eastern, and North African markets. Bio-Thera Solutions, Ltd. was founded in 2003 and is headquartered in Guangzhou, China.
Bio-Thera Solutions Ltd management
7- Mr. Shengfeng LiFounder, CEO, GM & Chairman · born 1959
- Ms. Zhan XianhongChief Financial Officer · born 1978
- Dr. Xianming HuangDeputy GM, SVP of Discovery Research & Director · born 1965
- Mr. Chaohe WangDirector & Head of the Clinical Department · born 1981
- Ms. Dan YuSecretary to the Board · born 1981
- Li Hua ShiAccounting Supervisor
- Mr. Cai BaoSenior Vice President of Quality & Director · born 1986